Analysts Are Bullish on These Healthcare Stocks: aTyr Pharma (LIFE), Minerva Neurosciences (NERV)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on aTyr Pharma (LIFEResearch Report), Minerva Neurosciences (NERVResearch Report) and Vir Biotechnology (VIRResearch Report) with bullish sentiments.

aTyr Pharma (LIFE)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma today and set a price target of $13.00. The company’s shares closed last Tuesday at $4.09.

According to TipRanks.com, Pantginis is a top 100 analyst with an average return of 44.6% and a 69.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Catabasis Pharmaceuticals, and Lineage Cell Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for aTyr Pharma with a $12.50 average price target.

See today’s analyst top recommended stocks >>

Minerva Neurosciences (NERV)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Minerva Neurosciences today and set a price target of $10.00. The company’s shares closed last Tuesday at $3.45, close to its 52-week low of $1.81.

According to TipRanks.com, Tsao is a 5-star analyst with an average return of 14.9% and a 56.8% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Crinetics Pharmaceuticals, and Protagonist Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Minerva Neurosciences with a $9.50 average price target.

Vir Biotechnology (VIR)

In a report released today, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Vir Biotechnology, with a price target of $125.00. The company’s shares closed last Tuesday at $38.96.

According to TipRanks.com, Trucchio is a 4-star analyst with an average return of 14.8% and a 62.7% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Precision BioSciences, and Flexion Therapeutics.

Vir Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $70.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.